New view of the heartbeat
The human cardiac voltage-gated sodium channel (Nav1.5) plays a critical role in maintaining regular heartbeats. Mutations in Nav1.5 cause life-threatening heart rhythm disorders (arrhythmias).
Nav1.5 is sensitive to the calcium-ion sensor protein calmodulin (CaM); however, the exact mechanism of how CaM exerts its effect on Nav1.5 is not well understood.
Christopher Johnson, PhD, Walter Chazin, PhD, and their colleagues integrated structural biology data from multiple techniques to show that CaM engages a portion of Nav1.5 known as the “inactivation gate” in a unique manner.
Then they determined that this calcium-dependent binding of CaM promotes the resetting of the channel after it opens, to help prepare for the next heartbeat.
Their work suggests a mechanism for how calcium and calmodulin fine tune cardiac sodium channels and may help in the development of novel therapeutics and improvements to existing treatments for cardiac arrhythmias.
Original publication
Most read news
Original publication
Christopher N. Johnson, Franck Potet, Matthew K. Thompson, Brett M. Kroncke, Andrew M. Glazer, Markus W. Voehler, Bjorn C. Knollmann, Alfred L. George Jr., Walter J. Chazin; "A Mechanism of Calmodulin Modulation of the Human Cardiac Sodium Channel"; Structure; 2018
Topics
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Breakthrough model holds promise for treating Graves' disease - Animal model first to simulate eye complications of thyroid disorder
Young's_syndrome

TechPivot GmbH - Berlin, Germany
ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for Vitreomacular Adhesion - Highly significant trial result (p=0.003) demonstrates the potential of microplasmin in the treatment of retinal disease

Protein could help in early detection of malignant Hodgkin's lymphoma
Mobile_phone_radiation_and_health
A new role for sodium in the brain - Findings identify a novel pharmacological target for drug development
Corallina_officinalis
Coronary_artery_bypass_surgery
Microsurgical_lumbar_laminoplasty
